Navigation Links
Instrumentation Laboratory Receives FDA Clearance to Expand the Intended Use of HemosIL(R) D-Dimer Assay

-Now for Exclusion of Venous Thromboembolism-

LEXINGTON, Mass., Aug. 28 /PRNewswire/ -- Instrumentation Laboratory (IL) today announced that the US Food and Drug Administration (FDA) has granted 510(k) clearance to expand the intended use for the HemosIL D-Dimer assay to exclude venous thromboembolism (VTE) in outpatients suspected of deep venous thrombosis (DVT) and pulmonary embolism (PE), when used in conjunction with a clinical pretest probability (PTP) assessment model. HemosIL D-Dimer was originally released in 1998, for the quantitative determination of D-Dimer in human citrated plasma and in 2005 was FDA cleared for use as an aid in the diagnosis of VTE.

As a part of the 510(k), IL performed a multi-center clinical study involving more than six-hundred patients in four different hospitals, according to a strict protocol reviewed through the FDA. Using a cut-off value of 230 ng/mL, the Negative Predicative Value was 100% for DVT and PE on the ACL TOP(R) Hemostasis Testing System and 100% for DVT and 99.1% for PE on the ACL ELITE(R) system.

In 2007, the FDA granted clearance for the same VTE exclusionary claims with IL's second-generation HemosIL D-Dimer HS assay. Both assays now have proven clinical performance for the exclusion of DVT and PE when used with a PTP assessment model and share the same cut-off value.

"This expanded intended use for our D-Dimer assay allows IL to provide the tools healthcare professionals need to more accurately and efficiently rule-out patients suspected of DVT and PE, regardless of the size of their institution or the throughput of their analyzers," said Giovanni Russi, Director of Worldwide Marketing, Hemostasis Reagents at IL. "We are passionate about developing innovative products and offering all of our customers a full range of solutions through our comprehensive portfolio of hemostasis reagents and instruments."

HemosIL D-Dimer is fully automated on ACL systems, with time to results in less than seven minutes. It was the first D-Dimer test automated on IL's ACL systems and since its launch, much has been published about its excellent performance for the diagnosis of both DVT and PE.

About VTE

DVT occurs when a blood clot forms in a large vein, usually in a leg. A potentially fatal PE happens if the blood clot breaks loose, migrates to the lungs and blocks a pulmonary artery or one of its branches. These conditions can occur after any surgery, as well as in patients with spinal fractures and spinal-cord injury, though it is most commonly seen in patients who have recently undergone orthopedic surgery. Two hundred thousand new cases of DVT and PE occur in the US annually and 20% suffer sudden death as a result of PE. Learn more by visiting

Instrumentation Laboratory ( ), founded in 1959, is a worldwide developer, manufacturer and distributor of in vitro diagnostic instruments, related reagents and controls for use primarily in hospitals and independent clinical laboratories. The company's product lines include critical care systems, hemostasis systems and information management systems. IL's GEM(R) product offerings, part of the critical care line, include the new GEM Premier 4000 analyzer with Intelligent Quality Management (iQM(R)), GEM Premier(TM) 3000 analyzer, GEM OPL(TM), a portable whole blood CO-Oximeter and the GEM PCL Plus, a portable coagulation analyzer. IL's hemostasis portfolio includes the ACL TOP(R) Family of Hemostasis Testing Systems, fully automated, high-productivity analyzers, including the ACL TOP and the new ACL TOP 500 CTS. IL also offers the ACL ELITE(R) and ELITE PRO, other hemostasis analyzers and the HemosIL(R) line of reagents. IL is based in Lexington, Massachusetts.

SOURCE Instrumentation Laboratory (IL)
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Alliance for Medical Devices, Instrumentation and Diagnostics formed between Fraunhofer Center for Manufacturing Innovation and Boston University
2. Instrumentation Laboratory Receives FDA Clearance to Expand the Intended Use for HemosIL(R) D-Dimer HS Assay
3. Thermo Fisher Scientific Selected by China Doping Control Center to Supply Testing Instrumentation for the 2008 Olympic Games in Beijing
4. HealthTrust Expands Contract With Instrumentation Laboratory for Critical Care Portfolio to Include Consorta
5. Cepheid and Instrumentation Laboratory Introduce Xpert(TM) HemosIL(R) FII & FV Assay to European Clinical Testing Market
6. Instrumentation Laboratory Ships 1000th GEM Premier 4000 Analyzer to Scripps Health
7. Instrumentation Laboratory to Celebrate 50th Anniversary With 50 and Forward Program
8. Instrumentation Laboratory Announces Contract for Multi-Parameter Testing Products with Broadlane
9. PerkinElmer Expertise and Solutions Integral to Food Safety Monitoring for the Beijing Games : Methods, Applications Expertise and Instrumentation Deployed in Mobile Laboratory
10. Pharmatek Adds Cytotoxic and High-Potent Drug Development Capabilities to San Diego Laboratory
11. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
Post Your Comments:
(Date:11/25/2015)... , November 26, 2015 ... Biobanking Market 2016 - 2020 report analyzes that ... integrity and quality in long-term samples, minimizing manual ... cost-effectiveness. Automation minimizes manual errors such as mislabeling ... efficiency. Further, it plays a vital role in ...
(Date:11/25/2015)... , Nov. 25, 2015  Neurocrine Biosciences, Inc. ... Gorman , President and CEO of Neurocrine Biosciences, will ... Conference in New York . ... visit the website approximately 5 minutes prior to the ... replay of the presentation will be available on the ...
(Date:11/25/2015)... ... November 25, 2015 , ... Jessica ... on AngelList early in their initial angel funding process. Now, they are paying ... looking to make early stage investments in the microbiome space. In this, ...
(Date:11/24/2015)... /CNW/ - iCo Therapeutics ("iCo" or "the Company") (TSX-V: ... the quarter ended September 30, 2015. Amounts, unless ... presented under International Financial Reporting Standards ("IFRS"). ... Andrew Rae , President & CEO of ... only value enriching for this clinical program, but ...
Breaking Biology Technology:
(Date:11/20/2015)... OXFORD, Connecticut , November 20, 2015 ... biometric authentication company focused on the growing mobile commerce ... its CEO, Gino Pereira , was recently interviewed ... The interview will air on this weekend on ... Bloomberg Latin America . --> NXTD ) ...
(Date:11/17/2015)... 17, 2015 Paris from ... --> Paris from 17 th until ... biometrics innovation leader, has invented the first combined scanner in ... same scanning surface. Until now two different scanners were required: ... can capture both on the same surface. This innovation ...
(Date:11/12/2015)...  A golden retriever that stayed healthy despite having ... provided a new lead for treating this muscle-wasting disorder, ... of MIT and Harvard and the University of São ... Cell, pinpoints a protective gene that boosts ... The Boston Children,s lab of Lou Kunkel , ...
Breaking Biology News(10 mins):